Polypharmacology in Drug Discovery
Jens-Uwe Peters
€ 152.50
FREE Delivery in Ireland
Description for Polypharmacology in Drug Discovery
Hardcover. Polypharmacology can be the two-faced Janus in drug discovery and pharmacology: an adverse, off-target safety risk in some cases or a necessity for effectively treating complex diseases like psychosis and cancer. Editor(s): Peters, Jens-Uwe. Num Pages: 536 pages, Illustrations. BIC Classification: MMG. Category: (P) Professional & Vocational. Dimension: 163 x 241 x 39. Weight in Grams: 1068.
An essential outline of the main facets of polypharmacology in drug discovery research
Extending drug discovery opportunities beyond the "one drug, one target" philosophy, a polypharmacological approach to the treatment of complex diseases is emerging as a hot topic in both industry and academic research. Polypharmacology in Drug Discovery presents an overview of the various facets of polypharmacology and how it can be applied as an innovative concept for developing medicines for treating bacterial infections, epilepsy, cancer, psychiatric disorders, and more. Filled with a collection of instructive case studies that reinforce the material and illuminate the subject, this practical guide:
... Read moreProduct Details
Format
Hardback
Publication date
2012
Publisher
John Wiley & Sons Inc United Kingdom
Number of pages
536
Condition
New
Number of Pages
536
Place of Publication
New York, United States
ISBN
9780470590904
SKU
V9780470590904
Shipping Time
Usually ships in 7 to 11 working days
Ref
99-1
About Jens-Uwe Peters
Jens-Uwe Peters, PhD, works in the Medicinal Chemistry Department at F. Hoffmann-La Roche. In his ten years at Roche, he has been involved in numerous drug discovery projects, has contributed to Early Safety Profiling initiatives, and has researched opportunities for polypharmacological drug discovery. Dr. Peters is author or coauthor on twenty-six journal papers and is named on twenty-two patents.
Reviews for Polypharmacology in Drug Discovery
“The book is well presented and the price is reasonable for anyone (drug designers, medicinal chemists, biochemists, biologists, clinicians and toxicologists) interested in any of the many facets that come together to make polypharmacology.” (British Toxicology Society, 1 July 2013) “However, anyone interested in the complex issues relating to drug promiscuity should find this very timely and topical ... Read more